Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASTURE: Spartalizumab concurrent plus consolidation versus consolidation only with standard chemotherapy in unresectable stage III NSCLC
KCT0004933Phase 2Withdrawn
- Sponsor
- Yonsei University Health System
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of spartalizumab in non-small cell lung cancer (NSCLC), sponsored by Yonsei University Health System. Planned start May 2020; status: withdrawn.
02
Drugs
spartalizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0004933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004933.